Some solid tumors are what oncologists call "immune cold": the immune system simply cannot see them. George Sens puts that at 90 to 95 percent of MSS colorectal cases, and notes five-year survival under 13 percent for pancreatic. His framing, borrowed from a doctor he heard it from: your first and last line of defense is your immune system. For these tumors, it is flying blind.

LurexBio sits upstream of the therapies you see advertised. Rather than replacing or boosting the immune system, its platform is designed to make cold tumors visible to it — and to do that non-genetically. George's analogy on the episode: the immune system is an airplane, the cold tumor is a pitch-black runway, and the company's job is to put the lights up so the plane can land.

The company came out of founder James Clark's own diagnosis. A layperson, not a physician, he was told he had stage IV prostate cancer, taught himself the immunology, and was startled to find nobody working the problem from this angle. He is still battling it, in the present tense. George came from revenue leadership in enterprise software, fintech and automotive, and describes his own job as building the company around the science.

Host Jonathan W. Buckley of The Artesian Network and George get into:

• What "immune cold" actually means, and why making a tumor visible has to come before treating it
• Evasion versus exclusion — two separate tumor problems, and which one the platform is aimed at
• Why the approach is deliberately non-genetic, and the "CSI effect" in medicine that makes everything default to DNA and mRNA
• What the company looked like when he arrived: science heavy, operationally skinny
• Standing up governance, a board and an advisory board before switching on named lab partnerships, not after
• Why this is not a software company: no MVP, no recurring revenue, and a near-term goal of proving the scientific thesis through preclinical
• The fundraising math that catches tech operators off guard — biotech seed rounds of three and a half to five million, A rounds of twenty-five to seventy-five
• Where the moat lives when you are not patenting a compound: a portfolio he puts at 27 provisional filings covering delivery and membrane attachment
• Why he argues the novel part is the combination of already-proven science, not a single new discovery
• The switch from selling businesses an improvement to working on something meant to make people's lives better

Connect with George
LinkedIn: linkedin.com/in/georgesens
LurexBio: lurexbio.com

Follow the show
YouTube: youtube.com/@theartesiannetwork
Spotify: open.spotify.com
Apple Podcasts: podcasts.apple.com

Every episode, on every platform: WeBuiltItBecauseWeHadTo.com

More from The Artesian Network: artesiannetwork.com

Almost every founder story on this show is told from the middle of the climb. This one is told from the other end.

Edgard Capdevielle spent about a decade as President and CEO of Nozomi Networks, one of the defining companies in OT and IoT security — a company he did not found. It was started by Andrea Carcano and Moreno Carullo; Edgard was brought in to run it. Under him Nozomi passed $100 million in annual revenue, reached sustained cash-flow break-even, and was acquired by Mitsubishi Electric. In July 2026 he handed the CEO seat back to co-founder Carcano and moved into an executive advisor role.

Host Jonathan W. Buckley of The Artesian Network and Edgard get into:

• What makes an operator take someone else's company and give it ten years
• What is actually at stake when industrial systems are exposed, for anyone who has never set foot on a plant floor
• Selling to plant operators and industrial engineers instead of IT — and what his security peers got wrong about that buyer
• What the company looked like the week he took over, and the first thing he decided had to change
• What a small startup has to prove before a large industrial operator will trust it with systems that cannot go down
• Culture, burn, repeatable sales and boards — which one actually kept him up at night
• Getting the non-founder CEO relationship right alongside two technical co-founders, and where it got tested
• The unglamorous, repetitive work behind $100M ARR that never makes a press release
• The bet on the next phase of OT security he thinks the market has not priced in
• What he would tell an operator about to take the CEO seat at a company someone else founded

Connect with Edgard
LinkedIn: linkedin.com/in/edgardcapdevielle
Nozomi Networks: nozominetworks.com

Follow the show
YouTube: youtube.com/@theartesiannetwork
Spotify: open.spotify.com
Apple Podcasts: podcasts.apple.com

Every episode, on every platform: WeBuiltItBecauseWeHadTo.com

More from The Artesian Network: artesiannetwork.com

Most companies record what they decided. Almost none record why, or what they considered and ruled out.

Ashutosh Garg, co-founder and CEO of Twin Cafe (formerly Viven), is building Digital Twins: AI assistants trained on how a specific person reasons, decides and communicates, with that person kept in the loop. It is his third company, after Bloomreach and Eightfold, and it started with a blood test, a two-day wait to see his doctor, and three hours with ChatGPT.

Host Jonathan W. Buckley of The Artesian Network and Ashutosh get into:

• Why generic AI chases average knowledge, when people really want the experience of someone they trust
• Keeping the human in the loop: review, edits and escalation to the real person
• A two-month pilot that ended with roughly 140,000 employees on the platform
• Augmentation vs. replacement, and why the quality of work is the real gain
• Whether "digital twin" is the right name for the category
• What enterprise knowledge management looks like in five years
• His advice to founders: trust and security are non-negotiable, and don't build around today's technology constraints

Every episode, on every platform: WeBuiltItBecauseWeHadTo.com